Centessa Pharmaceuticals plc ADR’s recently made public that its Officer Bush Tia L acquired Company’s shares for reported $0.5 million on Sep 09 ’25. In the deal valued at $20.00 per share,24,792 shares were bought.
Then, Accardi Mario Alberto bought 7,000 shares, generating $140,000 in total proceeds.
Before that, HUSSAIN IQBAL J bought 20,000 shares. Centessa Pharmaceuticals plc ADR shares valued at $400,102 were divested by the Officer at a price of $20.01 per share.
Wells Fargo initiated its Centessa Pharmaceuticals plc ADR [CNTA] rating to an Overweight in a research note published on September 03, 2025; the price target was $31. Truist began covering CNTA with “Buy” recommendation on July 21, 2025. Needham started covering the stock on May 28, 2025. It rated CNTA as “a Buy”.
Price Performance Review of CNTA
On Tuesday, Centessa Pharmaceuticals plc ADR [NASDAQ:CNTA] saw its stock jump 15.64% to $20.85. Over the last five days, the stock has gained 20.73%. Centessa Pharmaceuticals plc ADR shares have risen nearly 42.81% since the year began. Nevertheless, the stocks have risen 24.48% over the past one year. While a 52-week high of $19.09 was reached on 09/09/25, a 52-week low of $9.60 was recorded on 04/09/25.
Levels Of Support And Resistance For CNTA Stock
The 24-hour chart illustrates a support level at 18.96, which if violated will result in even more drops to 17.08. On the upside, there is a resistance level at 21.80. A further resistance level may holdings at 22.76.
How much short interest is there in Centessa Pharmaceuticals plc ADR?
A steep rise in short interest was recorded in Centessa Pharmaceuticals plc ADR stocks on 2025-08-15, growing by 0.97 million shares to a total of 4.65 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-15 was 3.67 million shares. There was a rise of 20.89%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 08, 2025 when Chardan Capital Markets began covering the stock and recommended ‘”a Buy”‘ rating along with a $30 price target.
